Did you mean?
Search Results - Showing 24 - 36 Of 50
_understanding-myeloma-treatment-types.jpg "What are the types of treatment available for myeloma? Myeloma expert Dr. Mark Schroeder reviews the myeloma treatment classes, including proteasome inhibitors, immunomodulatory drugs (iMids), and immunotherapy. Dr. Schroeder also discusses factors to consider when choosing therapy for patients with myeloma. nnDr. Mark Schroeder is a hematologist at Siteman Cancer Center of Washington University School of Medicine in St. Louis. Dr. Schroeder serves as Associate Professor in the Department of Med")
⏲ 3 min 44 sec ✓ 02-Dec-2022
_immunomodulatory-therapy-for-scleritis-and-mmp.jpg "Dr.Mohammad Khabbaz")
⏲ 12 minutes 23 seconds 👁 216
_pharmacology-of-blood-ar-immunomodulatory-agents.jpg "Clinical Pharmacology Lectures")
⏲ 58 minutes 57 seconds 👁 64.7K
_arbidol-brand-site-124-concept-development-and-production.jpg "It is an antiviral drug with immunomodulatory effect for the treatment of a variety of diseases, including influenza. One of the most famous medicines in Russia occupying a leading position in sales across the country. The new brand site helps the user to choose the right dosage, get recommendations on antiviral therapy, learn more about the treatment and diagnostic.")
⏲ 45 sec ✓ 21-Nov-2017
_what-are-immunomodulatory-drugs-imids-and-how-do-they-work.jpg "HealthTree University Myeloma")
⏲ 5 minutes 49 seconds 👁 3K
_myeloma-immunomodulatory-therapy-and-chip.jpg "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 2 minutes 12 seconds 👁 73
_citopsor-124-psoriasis-ointment-topical-cream-124-natural-ingredients.jpg "Balsam Citopsor is an innovative non-hormonal solid oil preparation for topical use, which heals the skin in dermatoses (psoriasis, eczema, versicolor lichen). nnBalsam Citopsor is an innovative non-hormonal solid oil preparation for topical use, which heals the skin in dermatoses (psoriasis, eczema, lichen). The drug effectively neutralizes the pathological manifestations - desquamation, itching and bleeding. It has anti-inflammatory, antibacterial, regenerating, antipruritic, analgesic and imm")
⏲ 17 sec ✓ 09-Jan-2019
_ucla-uveitis-fellowship-program.jpg "The UCLA Uveitis Fellowship is a one-year AUPO FCC Compliant fellowship providing comprehensive training in the evaluation and management of uveitis and other inflammatory eye diseases. The fellowship provides training in all aspects of clinical care, including immunomodulatory therapy, perioperative control of inflammation, procedures (including injections and paracentesis), and cataract surgery.nnFellows rotate with multiple uveitis specialists (Dr. Judy Chen, Dr. Michael Kapamajian, Dr. Gary")
⏲ 2 min 84 sec ✓ 04-Nov-2023
_9e-confrence-internationale-sur-la-molcule-hla-g-session-3.jpg "PLENARY SESSION 3nHLA-G, COVID AND PARASITE INFECTIONSnChairpersons: Roberta RIZZO, Jean-Philippe DESLYSnn nn15:40 Daria BORTOLOTTI (Italy)")
⏲ 82 min 59 sec ✓ 04-Jul-2022
_front-line-combinations-in-multiple-myeloma-highlights-from-eha-2017.jpg "Professor Joy Ho (Royal Prince Alfred Hospital, Sydney, Australia) and Professor Je-Jung Lee (Chairman, Korean Multiple Myeloma Working Party) discuss current treatment paradigms in newly diagnosed multiple myeloma (NDMM), recent advances in combination therapy from EHA and the potential impact on clinical practice in countries including Australia and South Korea.nnCurrent treatment practices for transplant eligible and transplant ineligible patients were discussed, noting key regional variation")
⏲ 5 min 87 sec ✓ 25-Jan-2018
_expert-panel-discussion-on-the-use-of-novel-therapies-in-multiple-myeloma.jpg "World Myeloma Forum Expert Panel members Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; Ravi Vij, MD, MBA; and Ola Landgren, MD, PhD discuss data presented at ASH 2017 on the use of Novel Therapies in Multiple Myeloma.nnThe panel discusses four (4) abstracts presented at ASH using Novel Therapies including Venetoclax, GSK2857916, and Selinexor and their implication in the management of patients with Multiple Myeloma:nnAbstract 3131: Phase 1 Study of Venetoclax in Combination with Dexamethasone As")
⏲ 5 min 75 sec ✓ 23-Jan-2018
_mutiple-myeloma-treatment-in-the-non-transplant-setting.jpg "Dr Sonia Zweegman and Prof Marivi Mateos talk to ecancertv at IMW 2013.nnDefining an elderly multiple myeloma (MM) patient can be difficult. Currently we use chronological age, defined as those aged 65 years or older. A second age group is those aged 75 years and older, who tend to be more unfit or frail. However, the use of biological age through geriatric assessment should be considered in the future.nnThe objective of treatment in elderly MM patients has changed with the arrival of novel ther")
⏲ 8 min 81 sec ✓ 16-Jan-2018
Related Searches
Search Videos
Recent Searches
_understanding-myeloma-treatment-types.webp "What are the types of treatment available for myeloma? Myeloma expert Dr. Mark Schroeder reviews the myeloma treatment classes, including proteasome inhibitors, immunomodulatory drugs (iMids), and immunotherapy. Dr. Schroeder also discusses factors to consider when choosing therapy for patients with myeloma. nnDr. Mark Schroeder is a hematologist at Siteman Cancer Center of Washington University School of Medicine in St. Louis. Dr. Schroeder serves as Associate Professor in the Department of Med")
_immunomodulatory-therapy-for-scleritis-and-mmp.webp "Dr.Mohammad Khabbaz")
_pharmacology-of-blood-ar-immunomodulatory-agents.webp "Clinical Pharmacology Lectures")
_arbidol-brand-site-124-concept-development-and-production.webp "It is an antiviral drug with immunomodulatory effect for the treatment of a variety of diseases, including influenza. One of the most famous medicines in Russia occupying a leading position in sales across the country. The new brand site helps the user to choose the right dosage, get recommendations on antiviral therapy, learn more about the treatment and diagnostic.")
_what-are-immunomodulatory-drugs-imids-and-how-do-they-work.webp "HealthTree University Myeloma")
_myeloma-immunomodulatory-therapy-and-chip.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_citopsor-124-psoriasis-ointment-topical-cream-124-natural-ingredients.webp "Balsam Citopsor is an innovative non-hormonal solid oil preparation for topical use, which heals the skin in dermatoses (psoriasis, eczema, versicolor lichen). nnBalsam Citopsor is an innovative non-hormonal solid oil preparation for topical use, which heals the skin in dermatoses (psoriasis, eczema, lichen). The drug effectively neutralizes the pathological manifestations - desquamation, itching and bleeding. It has anti-inflammatory, antibacterial, regenerating, antipruritic, analgesic and imm")
_ucla-uveitis-fellowship-program.webp "The UCLA Uveitis Fellowship is a one-year AUPO FCC Compliant fellowship providing comprehensive training in the evaluation and management of uveitis and other inflammatory eye diseases. The fellowship provides training in all aspects of clinical care, including immunomodulatory therapy, perioperative control of inflammation, procedures (including injections and paracentesis), and cataract surgery.nnFellows rotate with multiple uveitis specialists (Dr. Judy Chen, Dr. Michael Kapamajian, Dr. Gary")
_9e-confrence-internationale-sur-la-molcule-hla-g-session-3.webp "PLENARY SESSION 3nHLA-G, COVID AND PARASITE INFECTIONSnChairpersons: Roberta RIZZO, Jean-Philippe DESLYSnn nn15:40 Daria BORTOLOTTI (Italy)")
_front-line-combinations-in-multiple-myeloma-highlights-from-eha-2017.webp "Professor Joy Ho (Royal Prince Alfred Hospital, Sydney, Australia) and Professor Je-Jung Lee (Chairman, Korean Multiple Myeloma Working Party) discuss current treatment paradigms in newly diagnosed multiple myeloma (NDMM), recent advances in combination therapy from EHA and the potential impact on clinical practice in countries including Australia and South Korea.nnCurrent treatment practices for transplant eligible and transplant ineligible patients were discussed, noting key regional variation")
_expert-panel-discussion-on-the-use-of-novel-therapies-in-multiple-myeloma.webp "World Myeloma Forum Expert Panel members Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; Ravi Vij, MD, MBA; and Ola Landgren, MD, PhD discuss data presented at ASH 2017 on the use of Novel Therapies in Multiple Myeloma.nnThe panel discusses four (4) abstracts presented at ASH using Novel Therapies including Venetoclax, GSK2857916, and Selinexor and their implication in the management of patients with Multiple Myeloma:nnAbstract 3131: Phase 1 Study of Venetoclax in Combination with Dexamethasone As")
_mutiple-myeloma-treatment-in-the-non-transplant-setting.webp "Dr Sonia Zweegman and Prof Marivi Mateos talk to ecancertv at IMW 2013.nnDefining an elderly multiple myeloma (MM) patient can be difficult. Currently we use chronological age, defined as those aged 65 years or older. A second age group is those aged 75 years and older, who tend to be more unfit or frail. However, the use of biological age through geriatric assessment should be considered in the future.nnThe objective of treatment in elderly MM patients has changed with the arrival of novel ther")
![[+]](/images/menu.gif){kind=small}